Navigation Links
IRICoR and Université de Montréal license a novel program for early-onset morbid obesity to Pfizer
Date:10/2/2013

This news release is available in French.

The Institute for Research in Immunology and Cancer Commercialization of Research (IRICoR) and its host institution, the Universit de Montral (UdM) today announced the licensing to Pfizer Inc. of a novel early-onset morbid obesity pre-clinical program developed at the Institute for Research in Immunology and Cancer (IRIC).

Under the terms of the global license, Pfizer will fund pre-clinical research activities at IRIC and will be fully responsible for the clinical development and marketing of any resulting products. Pfizer will make an upfront payment to IRICoR, and IRICoR will be eligible to receive development and commercial milestone payments, as well as a tiered royalty on any product sales.

In certain people, genetic defects in the cellular trafficking of the melanocortin receptor type 4 (MC4R) lead to an early-onset morbid obesity, resulting in multiple life-threatening problems, for example, an increased risk of cancer.

Dr. Michel Bouvier, world-renowned expert in the field of G-protein coupled receptor signaling, has developed a new therapeutic approach to this disease based on small molecule called "pharmacological chaperones" that selectively bind to MC4R and correct its folding, trafficking and function. Cell-based assays and pre-clinical studies using a new proprietary animal model for MC4R-promoted obesity indicate that this is a potentially promising approach for treating familial early-onset morbid obesity resulting from MC4R mutations.

"We are very pleased to partner with Pfizer for the development of this promising scientific breakthrough," commented Johane Boucher-Champagne, Chairperson of IRICoR's Board of Directors. "The ability of IRICoR to identify and incubate innovative projects which appeal to industry leaders such as Pfizer further validates our business model of forging collaborations between academia and industry for drug discovery and development. We look forward to working closely with Pfizer to potentially develop new treatment options for this indication."

"Dr. Bouvier's team brings leading expertise in GPCR pharmacological chaperones that will enrich Pfizer's already strong chaperone program targeting genetic diseases characterized by protein misfolding. The collaboration is designed to combine our capabilities and resources with the goal of expediting potential new therapies for early-onset morbid obesity patients with MCR4 mutations" said Kevin Lee, Chief Scientific Officer, Pfizer's Rare Disease Research Unit.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related biology news :

1. UdeMs IRIC and IRICoR achieve important milestone in their collaboration with Bristol-Myers Squibb
2. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
3. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
4. ORNLs newly licensed neutron detector will advance human disease research
5. Research spinoff ReXceptor gets license for Alzheimers treatment
6. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
7. Inflection Biosciences licenses preclinical oncology programs from the CNIO
8. Local Pearle Vision Licensee Adds Second Center In Canton, Ohio
9. Researchers discover novel therapy for Crohns disease
10. New clinical trial explores novel noninvasive colon cancer screening test
11. Notre Dame researchers using novel method to combat malaria drug resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology: